维奈克拉在非霍奇金淋巴瘤治疗中的研究进展

Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin′s Lymphoma——Review

细胞凋亡异常与血液肿瘤的发生密切相关,BCL-2作为细胞固有程序性死亡的关键抗凋亡蛋白,近年来成为血液肿瘤治疗的热点。维奈克拉是美国食品和药物管理局批准的一种口服小分子选择性BCL-2抑制剂,用于治疗慢性淋巴细胞白血病患者或小淋巴细胞淋巴瘤患者以及不适合进行化疗的老年急性髓系白血病患者。此外,在非霍奇金淋巴瘤患者的治疗中也显示出良好的临床应用前景,这是维奈克拉临床应用的新拓展。本文就BCL-2蛋白家族在非霍奇淋巴瘤细胞凋亡调控中的作用、BCL-2抑制剂的开发以及维奈克拉治疗非霍奇金淋巴瘤的最新研究进展作一综述。

Abnormal cell apoptosis is closely related to the occurrence of hematologic tumors,B-cell lymphoma-2(BCL-2),as a key anti-apoptotic protein in intrinsic programmed cell death,has become a hot spot in the treatment of hematologic tumors in recent years. Venetoclax is an oral small-molecule selective BCL-2inhibitor approved by the Food and Drug Administration(FDA)for the treatment of chronic lymphocytic leukemia(CLL)patients or small lymphocytic lymphoma(SLL)patients and for the treatment of elderly acute myeloid leukemia(AML)patients that is not suitable for aggressive chemotherapy. In addition,it also showed a promising clinical application in treatment of nonHodgkin′s lymphoma(NHL)patients,which is a new expansion of the clinical indications for venetoclax. In this review,the role of BCL-2protein family played in the regulation of NHL cell apoptosis,the development of BCL-2inhibitors and the recent research progress of venetoclax in the treatment of NHL are reviewed.